|1.||Schellschmidt, Ilka: 2 articles (01/2006 - 08/2004)|
|2.||Kakiuchi, Yasuhiro: 1 article (03/2015)|
|3.||Kobayashi, Masaki: 1 article (03/2015)|
|4.||Miyamori, Daisuke: 1 article (03/2015)|
|5.||Ikegaya, Hiroshi: 1 article (03/2015)|
|6.||Idota, Nozomi: 1 article (03/2015)|
|7.||Li, Lingzhi: 1 article (07/2014)|
|8.||Sun, Lizhou: 1 article (07/2014)|
|9.||Zhang, Jinbei: 1 article (07/2014)|
|10.||Fu, Yi: 1 article (07/2014)|
01/01/2010 - "There was a significant reduction in terms of bleeding rate changes and menstrual bleeding duration in both Yasmin and LD group at the following next six months in comparison with before the consumption (p < 0.05). "
01/01/2010 - "The results of this study indicated that the bleeding rate in the Yasmin group within the next six month compared to taking them before was significantly lower than that in LD group (p = 0.02); but there was no significant difference in terms of menstrual bleeding duration and the two menstruation interval between the two groups (p = 0.2). "
05/01/2014 - "To assess the efficacy, bleeding pattern, cycle control and safety of a combined oral contraceptive (YAZ) containing drospirenone 3 mg and ethinylestradiol 20 µg in a 24+4-day regimen in China. "
01/01/2006 - "To assess the bleeding profile, acceptance and safety of an extended 126-day regimen of the oral contraceptive Yasmin [30 microg ethinylestradiol (EE) and 3 mg drospirenone (DRSP)]. "
01/01/2009 - "Both Yasmin and desogestrel have good efficacy on contraception and similar modes of menstrual bleeding. "
07/01/2004 - "Yasmin provides good cycle control for women with PCOS, with an improvement in acne over 6 months but not in other symptoms of the syndrome."
09/01/2008 - "Of the 3 COCs with an FDA indication for the treatment of moderate acne, only YAZ contains drospirenone, a progestin that combines no androgenic activity with antiandrogenic activity. "
04/01/2002 - "Our objective was to compare the effect of 30 microg ethinyl estradiol (EE)/3 mg DRSP (EE/DRSP; Yasmin, Schering AG, Berlin, Germany) with that of 35 microg EE/2 mg cyproterone acetate (EE/CPA; Diane-35, Schering AG, Berlin, Germany) on mild-to-moderate cases of acne. "
01/01/2008 - "Twenty-seven women with either severe papular or nodulocystic facial acne were treated with a combined oral contraceptive containing 30 mug ethinyl estradiol and 3 mg drospirenone (EE/DRSP; Yasmin) and spironolactone (SL) 100 mg taken daily. "
08/01/2004 - "This double-blind study compared the efficacy and tolerability of a combined oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone (EE/DRSP; Yasmin) with a triphasic preparation containing 35 microg EE and 0.180, 0.215, 0.250 mg norgestimate (EE/NGM; Pramino, also known as Ortho Tri-Cyclen) in the treatment of acne vulgaris. "
07/01/2013 - "We had experienced a patient, 24-year-old young woman with left inguinal pain on ambulation, and edema of left leg four months after taking Yasmin. "
01/01/2009 - "Some other values which improved in both two groups, especially the improvement of breast tenderness and pain and skin abnormality in Yasmin group (18.0%, 89/494; 12.6%, 62/494) was more distinct than that in desogestrel group (11.3%, 19/168; 5.4%, 9/168). "
03/01/2003 - "We also argued that there was no compelling published evidence that Yasmin offered any advantages over other, longer-established, COCs with regards to weight gain, skin condition or premenstrual symptoms. "
08/01/2002 - "Company advertising claims that Yasmin is "truly different", as reliable and safe as other COCs and is "the pill for well-being", with "no associated weight gain" and "a demonstrable positive effect" on premenstrual symptoms and skin condition. "
10/01/2006 - "It has been shown in many clinical trials that Yasmin is an efficacious oral contraceptive, lacking undesired effects as with other oral contraceptives such as weight gain. "
12/01/2002 - "(Yasmin, Schering AG, Berlin, Germany) provides reliable contraception and, due to a lack of sodium retention, may counteract cyclical weight gain and other symptoms related to estrogen-induced fluid retention."
|6.||Ethinyl Estradiol (Estinyl)
|7.||drospirenone and ethinyl estradiol combination (Yasmin)
|1.||Hormone Replacement Therapy (Therapy, Hormone Replacement)
|2.||Contraception (Birth Control)
|3.||Angioplasty (Angioplasty, Transluminal)